Vulvodynia and proctodynia treated with topical baclofen 5% and palmitoylethanolamide

Archives of Gynecology and Obstetrics

Volumn 290, Issue 2, 2014, Pages 389-393

  Keppel Hesselink, Jan M ^a   Kopsky, David J ^b   Sajben, Nancy L ^c  

^a Institute for Neuropathic Pain   (Netherlands)

^b Institute for Neuropathic Pain   (Netherlands)

^c SCRIPPS MEMORIAL HOSPITAL   (United States)

Author keywords

Baclofen; Cream; Glia; Pain; Palmitoylethanolamide; Pelvic; Proctodynia; Vulvodynia

Indexed keywords

BACLOFEN; DILTIAZEM; PALMIDROL; PEAPURE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; FEMALE; HEMORRHOID; HUMAN; NUMERIC RATING SCALE; PAIN; PAIN ASSESSMENT; PELVIC EXAMINATION; PHYSIOTHERAPY; PROCTODYNIA; RATING SCALE; RECTOSCOPY; RECTUM DISEASE; SCORING SYSTEM; SEXUAL INTERCOURSE; VAGINA ATROPHY; VAGINA DISCHARGE; VULVITIS; VULVODYNIA;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANUS DISEASES; BACLOFEN; COITUS; DRUG THERAPY, COMBINATION; ENDOCANNABINOIDS; ETHANOLAMINES; FEMALE; HUMANS; MUSCLE RELAXANTS, CENTRAL; PAIN; PALMITIC ACIDS; VULVODYNIA;

EID: 84904548655     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-014-3218-4     Document Type: Article

References (52)

1. Wesselmann U, Burnett AL, Heinberg LJ (1997) The urogenital and rectal pain syndromes. Pain 73(3):269-294 (Pubitemid 28021832)
2. Wesselmann U, Reich SG (1996) The dynias. Semin Neurol 16(1):63-74. doi:10.1055/s-2008-1040961 (Pubitemid 126447967)
3. Lehman JS, Sciallis GF (2008) Effective use of topical amitriptyline hydrochloride 2.5% and ketamine hydrochloride 0.5% for analgesia in refractory proctodynia. J drugs in derm 7(9):887-889
4. Reed BD, Harlow SD, Sen A, Legocki LJ, Edwards RM, Arato N, Haefner HK (2012) Prevalence and demographic characteristics of vulvodynia in a population-based sample. Am J Obstet Gynecol 206(2):170 e1-e9. doi:10.1016/j.ajog.2011.08.012
5. Xie Y, Shi L, Xiong X, Wu E, Veasley C, Dade C (2012) Economic burden and quality of life of vulvodynia in the United States. Curr Med Res Opin 28(4):601-608. doi:10.1185/030079 95.2012.666963
6. Patsatsi A, Vavilis D, Theodoridis TD, Kellartzis D, Sotiriadis D, Tarlatzis BC (2012) Vulvodynia: a case series of a poorly recognized entity. Clin Exp Obstet Gynecol 39(3):330-332
7. Leo RJ, Dewani S (2012) A systematic review of the utility of antidepressant pharmacotherapy in the treatment of vulvodynia pain. J Sex Med 10(10):2497-2505. doi:10.1111/j.1743-6109.2012.02915.x
8. Leo RJ (2013) A systematic review of the utility of anticonvulsant pharmacotherapy in the treatment of vulvodynia pain. Sex Med 10(8):2000-2008. doi:10.1111/jsm.12200
9. Donders GG, Bellen G (2012) Cream with cutaneous fibroblast lysate for the treatment of provoked vestibulodynia: a doubleblind randomized placebo-controlled crossover study. Low Genit Tract Dis 16(4):427-436. doi:10.1097/LGT.0b013e31825a2274
10. Pagano R, Wong S (2012) Use of amitriptyline cream in the management of entry dyspareunia due to provoked vestibulodynia. Low Genit Tract Dis 16(4):394-397. doi:10.1097/LGT.0b013e3 182449bd6
11. Goetsch MF (2012) Unprovoked vestibular burning in late estrogen-deprived menopause: a case series. Low Genit Tract Dis 16(4):442-446. doi:10.1097/LGT.0b013e31825c2d28
12. Alexander GM, Perreault MJ, Reichenberger ER, Schwartzman RJ (2007) Changes in immune and glial markers in the CSF of patients with complex regional pain syndrome. Brain Behav Immun 21(5):668-676. doi:10.1016/j.bbi.2006.10.009 (Pubitemid 46829771)
13. Nickel JC, Tripp DA, Pontari M, Moldwin R, Mayer R, Carr LK, Doggweiler R, Yang CC, Mishra N, Nordling J (2010) Psychosocial phenotyping in women with interstitial cystitis/painful bladder syndrome: a case control study. Urology 183(1):167-172. doi:10.1016/j.juro.2009.08.133
14. Nickel JC, Tripp DA, Pontari M, Moldwin R, Mayer R, Carr LK, Doggweiler R, Yang CC, Mishra N, Nordling J (2010) Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. Urology 184(4):1358-1363. doi:10.1016/j.juro.2010.06.005
15. Gur A, Oktayoglu P (2008) Status of immune mediators in fibromyalgia. Curr Pain Headache Rep 12(3):175-181
16. Kadetoff D, Lampa J, Westman M, Andersson M, Kosek E (2012) Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol 242(1-2):33-38. doi:10.1016/j.jneuroim.2011.10.013
17. Ji RR, Berta T, Nedergaard M (2013) Glia and pain: is chronic pain a gliopathy? Pain. doi:10.1016/j.pain.2013.06.022
18. Vollmer-Conna U, Lloyd A, Hickie I, Wakefield D (1998) Chronic fatigue syndrome: an immunological perspective. Aust NZ J psychiatry 32(4):523-527 (Pubitemid 28393514)
19. Stringer EA, Baker KS, Carroll IR, Montoya JG, Chu L, Maecker HT, Younger JW (2013) Daily cytokine fluctuations, driven by leptin, are associated with fatigue severity in chronic fatigue syndrome: evidence of inflammatory pathology. Trans Med 11:93. doi:10.1186/1479-5876-11-93
20. Bornstein J, Tuma R, Farajun Y, Azran A, Zarfati D (2010) Topical nifedipine for the treatment of localized provoked vulvodynia: a placebo-controlled study. J pain 11(12):1403-1409. doi:10.1016/j.jpain.2010.03. 016
21. Walsh KE, Berman JR, Berman LA, Vierregger K (2002) Safety and efficacy of topical nitroglycerin for treatment of vulvar pain in women with vulvodynia: a pilot study. JGSM 5(4):21-27 (Pubitemid 35469408)
22. Kopsky DJ, Keppel Hesselink JM (2012) High doses of topical amitriptyline in neuropathic pain: two cases and literature review. Pain pract 12(2):148-153. doi:10.1111/j.1533-2500.2011.00477.x
23. Keppel Hesselink JM, Kopsky DJ (2013) Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells. Pain Res 6:239-245. doi:10.2147/JPR.S42417
24. Kopsky DJ, Keppel Hesselink JM (2013) Neuropathic pain due to acromegaly, treated with topical baclofen cream. J Pain Symptom Manage (In Press)
25. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD 3rd, Kugler JW, Hoff KL, Reddy PS, Rowland KM Jr, Riepl M, Christensen B, Loprinzi CL (2011) A double-blind, placebo-controlled trial of a topical treatment for chemotherapyinduced peripheral neuropathy: NCCTG trial N06CA. Support care cancer 19(6):833-841. doi:10.1007/s00520-010-0911-0
26. Nyirjesy P, Lev-Sagie A, Mathew L, Culhane JF (2009) Topical Amitriptyline-Baclofen Cream for the Treatment of Provoked Vestibulodynia. J Lower Genital Tract Disease 13(4):230-236
27. Whitehead RA, Puil E, Ries CR, Schwarz SK, Wall RA, Cooke JE, Putrenko I, Sallam NA, MacLeod BA (2012) GABA(B) receptor-mediated selective peripheral analgesia by the nonproteinogenic amino acid, isovaline. Neuroscience 213:154-160. doi:10.1016/j.neuroscience.2012.04.026
28. Reis GM, Duarte ID (2006) Baclofen, an agonist at peripheral GABAB receptors, induces antinociception via activation of TEA-sensitive potassium channels. Br J Pharmacol 149(6):733-739. doi:10.1038/sj.bjp.0706898 (Pubitemid 44748065)
29. Andoh T, Sugiyama K, Fujita M, Iida Y, Nojima H, Saiki I, Kuraishi Y (2008) Pharmacological evaluation of morphine and non-opioid analgesic adjuvants in a mouse model of skin cancer pain. Biol Pharm Bulletin 31(3):520-522 (Pubitemid 351442151)
30. Benke D, Zemoura K, Maier PJ (2012) Modulation of cell surface GABA(B) receptors by desensitization, trafficking and regulated degradation. World Biolo chem 3(4):61-72. doi:10.4331/wjbc.v3.i4.61
31. Roenker NL, Gudelsky GA, Ahlbrand R, Horn PS, Richtand NM (2012) Evidence for involvement of nitric oxide and GABA(B) receptors in MK-801- stimulated release of glutamate in rat prefrontal cortex. Neuropharmacology 63(4):575-581. doi:10.1016/j.neuropharm.2012.04.032
32. Carlton SM, Hargett GL, Coggeshall RE (1995) Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skin. Neurosci Lett 197(1):25-28
33. Davidson EM, Coggeshall RE, Carlton SM (1997) Peripheral NMDA and non-NMDA glutamate receptors contribute to nociceptive behaviors in the rat formalin test. NeuroReport 8(4):941-946 (Pubitemid 27152151)
34. Schmid HH (2000) Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? Chem Phys Lipids 108(1-2):71-87
35. M. KHJ, T. dB, R. W (2013) Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common cold. Int J Inflammation (In Press)
36. Keppel Hesselink JM, de Boer T, Witkamp RF (2013) Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common cold. Int J Inflam 2013:151028. doi:10.1155/2013/151028
37. Bachur NR, Masek K, Melmon KL, Udenfriend S (1965) Fatty acid amides of ethanolamine in mammalian tissues. J Biol Chem 240:1019-1024
38. Keppel Hesselink JM (2013) Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PAR-α agonist and effective nutraceutical. J Pain Res 6:625-634
39. Scuderi C, Valenza M, Stecca C, Esposito G, Carratu MR, Steardo L (2012) Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator- activated receptor-alpha. J Neuroinflammation 9:49. doi:10.1186/1742-2094-9-21
40. D'Agostino G, Russo R, Avagliano C, Cristiano C, Meli R, Calignano A (2012) Palmitoylethanolamide protects against the amyloid-beta25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. Neuropsychopharmacology 37(7):1784-1792. doi:10.1038/npp.2012.25
41. Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P, Piomelli D, Calignano A, Cuzzocrea S (2008) Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharm Exp Ther 326(1):12-23. doi:10.1124/jpet.108.136903 (Pubitemid 351872139)
42. Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C, Federico V, Petrucci MT, Cruccu G (2011) Palmitoylethanolamide restores myelinated-fibre function in patients with chemo-therapy- induced painful neuropathy. CNS Neurol Disord Drug Targ 10(8):916-920
43. Di Cesare MannelliL, D'Agostino G, Pacini A, Russo R, Zanardelli M, Ghelardini C, Calignano A (2013) Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PAR-alphamediated mechanism. Mediators Inflamm 2013:328797. doi:10.1155/2013/ 328797
44. Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B (2013) Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol Disord Drug Targ 12(1):34-44
45. Esposito E, Cuzzocrea S (2013) Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. CNS Neurol Disord Drug Targ 12(1):55-61
46. Luongo L, Guida F, Boccella S, Bellini G, Gatta L, Rossi F, de Novellis V, Maione S (2013) Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol Disord Drug Targ 12(1):45-54
47. Skaper SD, Facci L (2012) Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Philos Trans R Soc Lond B Biol Sci 367(1607):3312-3325. doi:10.1098/rstb.2011.0391
48. Keppel Hesselink JM (2012) New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide. Open Pain J 5:12-23
49. Keppel Hesselink JM, Hekker TA (2012) Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res 5:437-442. doi:10.2147/JPR.S32143
50. Indraccolo U, Barbieri F (2010) Effect of palmitoylethanolamidepolydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. Eur J Obstet Gynecol Reprod Biol 150(1):76-79. doi:10.1016/j.ejogrb.2010.01.008
51. Palomba R, De Simone MG, Giovannini A, Bonaccia P, Pinto D Use of palmitotlethanolamide (PEA) + polydatina in the chronic pelvic pain. In: SIAARTI, Parma, Italy, 2010.
52. Calabro RS, Gervasi G, Marino S, Mondo PN, Bramanti P (2010) Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide. Pain Med 11(5):781-784. doi:10.1111/j.1526-4637.2010. 00823.x